niacinamide has been researched along with Neoplasms, Pleural in 10 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is well tolerated in patients with mesothelioma after completion of platinum-containing chemotherapy." | 9.17 | Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. ( Barrington, S; Cane, P; Dunn, JT; Lal, R; Landau, D; Lang-Lazdunski, L; McLennan, B; Papa, S; Popat, S; Prevost, AT; Shah, R; Spicer, J; Viney, Z, 2013) |
| "We analyzed the molecular mechanisms of the antiproliferative effects of sorafenib in mesothelioma TIC cultures." | 7.85 | The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells. ( Barbieri, F; Carra, E; Daga, A; Favoni, RE; Filiberti, RA; Florio, T; Marubbi, D; Mutti, L; Pattarozzi, A; Würth, R, 2017) |
| "Sorafenib is a potent inhibitor of the ras/raf/MEK pathway and also targets VEGFR and cKIT." | 6.75 | A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. ( Crawford, J; Dubey, S; Heinze, R; Jänne, PA; Kindler, HL; Kratzke, R; Krug, L; Pang, H; Vokes, E; Wang, X; Watt, C, 2010) |
| "Sorafenib is well tolerated in patients with mesothelioma after completion of platinum-containing chemotherapy." | 5.17 | Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. ( Barrington, S; Cane, P; Dunn, JT; Lal, R; Landau, D; Lang-Lazdunski, L; McLennan, B; Papa, S; Popat, S; Prevost, AT; Shah, R; Spicer, J; Viney, Z, 2013) |
| "We analyzed the molecular mechanisms of the antiproliferative effects of sorafenib in mesothelioma TIC cultures." | 3.85 | The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells. ( Barbieri, F; Carra, E; Daga, A; Favoni, RE; Filiberti, RA; Florio, T; Marubbi, D; Mutti, L; Pattarozzi, A; Würth, R, 2017) |
| "THERE WERE 62 PATIENTS (37 MEN, MEAN AGE: 61 years) treated with sorafenib (62%), sunitinib (22%), and vandetanib (16%) outside of clinical trials; 22 had papillary, five had follicular, five had Hürthle cell, 13 had poorly differentiated, and 17 had medullary thyroid carcinoma (MTC)." | 3.80 | Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. ( Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M, 2014) |
| "Sorafenib is a potent inhibitor of the ras/raf/MEK pathway and also targets VEGFR and cKIT." | 2.75 | A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. ( Crawford, J; Dubey, S; Heinze, R; Jänne, PA; Kindler, HL; Kratzke, R; Krug, L; Pang, H; Vokes, E; Wang, X; Watt, C, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pattarozzi, A | 1 |
| Carra, E | 1 |
| Favoni, RE | 1 |
| Würth, R | 1 |
| Marubbi, D | 1 |
| Filiberti, RA | 1 |
| Mutti, L | 1 |
| Florio, T | 1 |
| Barbieri, F | 1 |
| Daga, A | 1 |
| Papa, S | 1 |
| Popat, S | 1 |
| Shah, R | 1 |
| Prevost, AT | 1 |
| Lal, R | 1 |
| McLennan, B | 1 |
| Cane, P | 1 |
| Lang-Lazdunski, L | 1 |
| Viney, Z | 1 |
| Dunn, JT | 1 |
| Barrington, S | 1 |
| Landau, D | 1 |
| Spicer, J | 1 |
| Massicotte, MH | 1 |
| Brassard, M | 1 |
| Claude-Desroches, M | 1 |
| Borget, I | 1 |
| Bonichon, F | 1 |
| Giraudet, AL | 1 |
| Do Cao, C | 1 |
| Chougnet, CN | 1 |
| Leboulleux, S | 1 |
| Baudin, E | 1 |
| Schlumberger, M | 1 |
| de la Fouchardière, C | 1 |
| Simonelli, M | 1 |
| Zucali, PA | 1 |
| Suter, MB | 1 |
| Lorenzi, E | 1 |
| Rubino, L | 1 |
| Fatuzzo, G | 1 |
| Alloisio, M | 1 |
| Santoro, A | 1 |
| Pignochino, Y | 1 |
| Dell'Aglio, C | 1 |
| Inghilleri, S | 1 |
| Zorzetto, M | 1 |
| Basiricò, M | 1 |
| Capozzi, F | 1 |
| Canta, M | 1 |
| Piloni, D | 1 |
| Cemmi, F | 1 |
| Sangiolo, D | 1 |
| Gammaitoni, L | 1 |
| Soster, M | 1 |
| Marchiò, S | 1 |
| Pozzi, E | 1 |
| Morbini, P | 1 |
| Luisetti, M | 1 |
| Aglietta, M | 1 |
| Grignani, G | 1 |
| Stella, GM | 1 |
| Azad, A | 1 |
| Herbertson, RA | 1 |
| Pook, D | 1 |
| White, S | 1 |
| Mitchell, PL | 1 |
| Tebbutt, NC | 1 |
| Desar, IM | 1 |
| Mulder, SF | 1 |
| Stillebroer, AB | 1 |
| van Spronsen, DJ | 1 |
| van der Graaf, WT | 1 |
| Mulders, PF | 1 |
| van Herpen, CM | 1 |
| Katz, SI | 1 |
| Zhou, L | 1 |
| Chao, G | 1 |
| Smith, CD | 1 |
| Ferrara, T | 1 |
| Wang, W | 1 |
| Dicker, DT | 1 |
| El-Deiry, WS | 1 |
| Hou, MM | 1 |
| Hsieh, JJ | 1 |
| Chang, NJ | 1 |
| Huang, HY | 1 |
| Wang, HM | 1 |
| Chuang, CK | 1 |
| Hsu, T | 1 |
| Chang, JW | 1 |
| Dubey, S | 1 |
| Jänne, PA | 1 |
| Krug, L | 1 |
| Pang, H | 1 |
| Wang, X | 1 |
| Heinze, R | 1 |
| Watt, C | 1 |
| Crawford, J | 1 |
| Kratzke, R | 1 |
| Vokes, E | 1 |
| Kindler, HL | 1 |
1 review available for niacinamide and Neoplasms, Pleural
| Article | Year |
|---|---|
Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Histone Deacetylase In | 2015 |
2 trials available for niacinamide and Neoplasms, Pleural
| Article | Year |
|---|---|
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; | 2013 |
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; | 2010 |
7 other studies available for niacinamide and Neoplasms, Pleural
| Article | Year |
|---|---|
The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Separation; C | 2017 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; | 2014 |
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyt | 2015 |
Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma.
Topics: Administration, Oral; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols | 2009 |
The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidn | 2009 |
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Caspase 3; Cell Line, Tumor; Extracell | 2009 |
Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chromosomes, Human, X; Disease-Free | 2010 |